US agency opens offices in India
This article was originally published in SRA
As part of its efforts to better guarantee the quality of food, drug and medical device imports, the US Food and Drug Administration has set up its first offices in India, in New Delhi and Mumbai1. The agency also recently opened offices in China, the European Union (in Brussels, Belgium), and in Latin America and there are plans to set up offices elsewhere in Latin America and also in the Middle East2,3.
You may also be interested in...
EU marketing applications from Vertex and Roche have reverted to standard review timelines at the European Medicines Agency. The outcomes of three fast-track requests that companies have made for their planned filings are still unknown.
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
KTE-X19, Kite’s potential new CAR-T therapy, will in the end be fast-tracked at the European Medicines Agency. Lilly failed to secure the speedy review it was seeking for selpercatinib